Shots:

• Amgen anticipates no disruption in its supply of medicines for patients across the globe due to COVID-19 and is expected to have no shortage of its therapies
• The company has temporarily paused the enrollment/screening in clinical studies to ensure the safety of subjects or integrity of data during a pandemic
• Amgen reported that P-II study of AMG 510 for NSCLC- P-III study of Tezepelumab for Asthma in collaboration with AstraZeneca and P-III study of omecamtiv mecarbil for HF in collaboration with Cytokinetics are all fully enrolled- and does not anticipate any delays in obtaining results

Click here ­to­ read full press release/ article | Ref: Amgen | Image: Amgen